Moderna, Inc. (MRNA) — Earnings Call X-Ray
Our AI read all 26 of MRNA's earnings calls (2019–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
D
Q4 2024
Calls Analyzed
26
2019–2025
Avg Candor
6.4/9
evasion 3.3/9
Call-by-call analysis
🔒 Q1 2025 earnings call
2025-05-01
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2025 call grade is ready
The full 37-point AI read of MRNA's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
D
Q4 2024 earnings call
2025-02-14
move ±19.8%
Management lowered guidance against slowing demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: loweredDemand: slowingMargins: contractingBacklog: shrinkingPricing: under pressureHeadcount: cuttingCapex: increasing 14 analysts · 26 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q3 2024 earnings call
2024-11-07
move ±13.3%
Management held guidance steady against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: mixedMargins: expandingBacklog: stablePricing: stableCapex: increasing 11 analysts · 20 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubtsFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
F
Q2 2024 earnings call
2024-08-01
move ±19.2%
Management lowered guidance against slowing demand and contracting margins. The delivery was rich in specifics.
Guidance: loweredDemand: slowingMargins: contractingBacklog: shrinkingPricing: under pressureHeadcount: cuttingCapex: flat 12 analysts · 22 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead⚑ Reads rehearsedFounder-ledHidden segment
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q1 2024 earnings call
2024-05-02
move ±10.3%
Management held guidance steady against slowing demand and contracting margins. The delivery was rich in specifics.
Guidance: maintainedDemand: slowingMargins: contractingPricing: under pressureHeadcount: flatCapex: decreasing 12 analysts · 25 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
D
Q4 2023 earnings call
2024-02-22
move ±13.8%
Management held guidance steady against slowing demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: slowingMargins: contractingBacklog: shrinkingPricing: stableHeadcount: cuttingCapex: increasing 10 analysts · 11 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedFounder-ledHidden segmentDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q3 2023 earnings call
2023-11-02
move ±16.7%
Management raised guidance against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: raisedDemand: mixedMargins: contractingBacklog: shrinkingPricing: raisingCapex: decreasing 9 analysts · 12 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedFounder-ledDirection beats results
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
1 more research questions answered NO
C
Q2 2023 earnings call
2023-08-03
move ±9.2%
Management lowered guidance against contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: loweredMargins: contractingBacklog: stablePricing: under pressureHeadcount: growingCapex: increasing 11 analysts · 20 questions
⚑ Critic ammunition✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsedFounder-led
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q1 2023 |
2023-05-04 |
C |
maintained | slowing | contracting |
7/9 |
4/9 |
| Q4 2022 |
2023-02-23 |
C |
maintained | slowing | contracting |
7/9 |
3/9 |
| Q3 2022 |
2022-11-03 |
D |
lowered | slowing | contracting |
6/9 |
4/9 |
| Q2 2022 |
2022-08-03 |
C |
maintained | slowing | contracting |
6/9 |
3/9 |
| Q1 2022 |
2022-05-04 |
C+ |
maintained | stable | contracting |
7/9 |
2/9 |
| Q4 2021 |
2022-02-24 |
D |
maintained | mixed | contracting |
6/9 |
4/9 |
| Q3 2021 |
2021-11-05 |
D |
lowered | mixed | expanding |
7/9 |
4/9 |
| Q2 2021 |
2021-08-05 |
B+ |
raised | accelerating | expanding |
6/9 |
2/9 |
| Q1 2021 |
2021-05-07 |
B+ |
raised | accelerating | expanding |
7/9 |
3/9 |
| Q1 2021 |
2021-04-14 |
B+ |
raised | accelerating | expanding |
7/9 |
2/9 |
| Q4 2020 |
2021-02-25 |
B+ |
raised | accelerating | expanding |
7/9 |
2/9 |
| Q3 2020 |
2020-10-29 |
B |
raised | accelerating | unclear |
7/9 |
4/9 |
| Q2 2020 |
2020-08-05 |
C+ |
raised | accelerating | unclear |
6/9 |
4/9 |
| Q1 2020 |
2020-05-07 |
D |
maintained | accelerating | unclear |
6/9 |
4/9 |
| Q4 2019 |
2020-02-26 |
D |
maintained | unclear | unclear |
6/9 |
4/9 |
| Q3 2019 |
2019-11-08 |
B+ |
raised | stable | unclear |
7/9 |
3/9 |
| Q2 2019 |
2019-08-08 |
F |
maintained | unclear | contracting |
6/9 |
5/9 |
| Q1 2019 |
2019-05-09 |
D |
none | unclear | contracting |
6/9 |
4/9 |
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← MRMD All “M” companies
MRNS →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.